The invention belongs to the technical field of
biology, and relates to a pharmaceutical composition containing mesenchymal stem cells and application. By controlling the using time, the medication mode and the dosage of the mesenchymal stem cells and the
vitamin D, the synergistic effect of the mesenchymal stem cells and the
vitamin D is achieved, the
cortical bone mineral density can be effectively improved, meanwhile, the bone trabecula density and the bone trabecula
cell density can be improved, and the
bone quality is improved. In addition, during formation and distribution of the bone trabecula, the thickness of the bone trabecula, the distance between the bone trabecula and the number of the bone trabecula can be improved, and the biological performance of thighbone and
lumbar vertebra bones is effectively improved. According to the technical scheme that the MSC and the
RANKL inhibitor are combined for use, the MSC and the
RANKL inhibitor have a synergistic effect, various functional indexes of
osteoporosis can be comprehensively improved, obviously, the MSC and the
RANKL inhibitor are combined for use, the thickness of bone trabecula, the distance between the bone trabecula and the number of the bone trabecula can be effectively improved, the biomechanical property of
tibia is effectively improved, and a good reference basis is provided for clinical application.